ROCKVILLE, Md., March 11, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a clinical-stage vaccine company, announced today that Frederick Driscoll, Chief Financial Officer of Novavax, will be presenting at the ROTH 23rd Annual OC Growth Stock Conference on March 14th, 2011 at 3:00 pm local time at The Ritz Carlton, Laguna Niguel, CA. A live audio-only webcast link for the presentation can be accessed via the Company website at www.novavax.com under Investors/Events, and a replay will be available for 90 days after the presentation.
About Novavax
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary virus-like particles (VLPs) technology and single-use bioprocessing system enables rapid vaccine development and production where and when it's needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
SOURCE Novavax, Inc.